Overview
Lactobacillus crispatus is one of the defining bacteria of a healthy vaginal microbiome. It is a lactic-acid-producing species that, when dominant, helps keep the vaginal environment acidic and inhospitable to the organisms associated with bacterial vaginosis (BV) and other reproductive tract infections.
Around 70% of women have a Lactobacillus-dominated vaginal microbiota, and in any one woman a single species can make up roughly 99% of the bacteria present. L. crispatus is one of the four species most frequently found in that dominant role, alongside L. gasseri, L. jensenii, and L. iners.[1] A Lactobacillus-dominated community is considered a good marker of a healthy vaginal ecosystem.[1]
L. crispatus has also become a leading candidate for live biotherapeutics: rather than taking a general probiotic by mouth, a specific vaginal strain is delivered directly to restore a protective community after BV treatment.
Classification
- Phylum: Bacillota (formerly Firmicutes)
- Family: Lactobacillaceae
- Genus: Lactobacillus
- Species: L. crispatus
In 2020, a genome-based revision split the sprawling genus Lactobacillus, then 261 species, into 25 genera. Familiar probiotics were renamed in the process; for example, L. rhamnosus became Lacticaseibacillus rhamnosus.[2] L. crispatus was one of the species that kept the Lactobacillus name, so older and newer literature refer to it the same way.
How L. crispatus Protects the Vaginal Environment
Lactic acid and low pH
The key protective mechanism is lactic acid. A study that measured vaginal fluid under realistic, low-oxygen conditions in women with Lactobacillus-dominated microbiota found an average pH of 3.5 (range 2.8–4.2) and total lactate of about 1%. That is roughly five times more acidic than earlier estimates. At that pH, the microbicidal protonated form of lactic acid was about eleven-fold more concentrated than prior research suggested.[3] This acidity is a direct chemical barrier against many bacterial and viral pathogens.[1]
Community stability
The balance of the vaginal microbiome is not fixed. It can shift quickly with menstruation, sexual activity, pregnancy, and infections.[1] When lactobacilli lose dominance, microbial diversity rises and organisms such as Gardnerella vaginalis expand, the pattern that characterizes bacterial vaginosis.
Vaginal Community Types
A landmark sequencing study of 396 asymptomatic North American women from four ethnic groups found that vaginal bacterial communities cluster into five groups. Four are dominated by a single Lactobacillus species (L. iners, L. crispatus, L. gasseri, or L. jensenii). The fifth has fewer lactic acid bacteria and more strictly anaerobic organisms.[4]
Two findings from that study are important context for anyone reading a vaginal microbiome test:
- Community types differ across ethnic groups. The proportion of each community type varied significantly among white, Black, Hispanic, and Asian women, and so did average vaginal pH: 4.2 in white, 4.4 in Asian, 4.7 in Black, and 5.0 in Hispanic women.[4]
- "Healthy" is not one profile. Lactic acid production appeared to be conserved across all community types, and the authors argued for a more refined definition of what counts as a normal vaginal community.[4]
The practical takeaway is that a result showing a community other than L. crispatus is not automatically abnormal.
Clinical Evidence: L. crispatus for Recurrent BV
BV is common, affecting an estimated 15–50% of reproductive-age women, and it frequently recurs after antibiotic treatment.[5] That high recurrence rate is what makes a restorative approach appealing.
In a randomized, double-blind, placebo-controlled phase 2b trial, 228 women who had just completed vaginal metronidazole were assigned to vaginally administered L. crispatus CTV-05 (Lactin-V) or placebo for 11 weeks:[5]
| Outcome | L. crispatus CTV-05 | Placebo |
|---|---|---|
| BV recurrence by week 12 | 30% | 45% |
| Risk ratio, week 12 | 0.66 (95% CI 0.44–0.87) | — |
| Risk ratio, week 24 | 0.73 (95% CI 0.54–0.92) | — |
Three caveats keep this in perspective. It tested one strain at one dose, delivered vaginally, as an investigational product in a trial setting. Results from this strain cannot be assumed for other L. crispatus products or for oral probiotics. It was also a phase 2b trial, so larger confirmatory trials are still important.
For the broader evidence on probiotics for vaginal infections, including the oral L. rhamnosus GR-1 and L. reuteri RC-14 combination, see our guide to probiotics for BV and yeast infections.
Supporting a Lactobacillus-Dominant Microbiome
The evidence for specific consumer interventions is still developing. Practical, low-risk steps include avoiding douching, which disrupts the vaginal ecosystem; seeking prompt treatment for BV rather than letting it persist; and discussing evidence-based probiotic options with a clinician. Our probiotics for vaginal health guide and the women's vaginal and urinary health protocol cover these options in more detail.
When to See a Clinician
See a clinician for unusual vaginal discharge, odor, itching, burning, or recurrent infections, and before starting any vaginal product during pregnancy. BV, yeast infections, and sexually transmitted infections can cause overlapping symptoms but need different treatment.
This page is for educational purposes and is not medical advice. Consult a qualified healthcare provider about vaginal symptoms or test results.